Dry Age-Related Macular Degeneration Market
This degenerative eye disease is caused by the thinning of the macula and interferes with a clear vision in the elderly. The macula is part of the retina that facilitates clear vision; when this part of the eye deteriorates, it causes blurred or distorted vision. But this does not mean that the individual will lose his or her sight, only the central vision is affected by this degenerative disease, and the peripheral vision remains intact. Vision loss is slow and can be corrected using innovative ocular treatments. It has been estimated that the Dry Age-Related Macular Degeneration Market has seen a jump due to increased research in drugs, rising amount of COVID-19 cases among the old and age-restricted chronic diseases.
The Dry Age-Related Macular Degeneration Market Size is expected to cross USD 15,351.07 million by 2027 at a CAGR of 8.20% during the forecast period
List of Dry Age-Related Macular Degeneration Market Players Covered in this report:
Santen Pharmaceuticals Inc. (Japan), Allergan plc (Ireland), Bausch Health (Canada), Alimera Science Inc. (US), Phio Pharmaceuticals Corp (US), Ocumension Therapeutics Co. Ltd (China), Belite Bio Inc. (US), Kubota Vision Inc. (US), Iveric Bio (US), Eyestem Research Pvt Ltd (India), Yuyang DNU Co., Ltd (South Korea), Stealth Biotherapeutics Inc. (US)
The global Dry Age-Related Macular Degeneration Market has been divided based on stages, age group, route of administration, diagnosis& treatment, and end user.
- The market, based on stages, has been segregated into early age-related macular degeneration, intermediate age-related macular degeneration, and late age-related macular degeneration.
- Based on age group, the dry AMD market has been divided into above 75 years, above 60 years, and above 40 years.
- Based on diagnosis & treatment, the dry AMD market has been divided into treatment and diagnosis.
- Treatment type is further bifurcated into nutrition therapy and telescopic lens implant. Nutrition therapy is again divided into antioxidants and others. Antioxidants areal so segregated as vitamins, zinc, copper, omega-3 fatty acids, and others.
- Diagnosis is bifurcated into fluorescein angiogram, preliminary test, optical coherence tomography, and others.
- Based on route of administration, the market is bifurcated into oral, intravitreal, and others.
- On the basis of end user, the market is bifurcated into hospitals and clinics, diagnostic centers, academic research institutes, and others
Dry Age-Related Macular Degeneration Market Share
It has been reported by the American Academy of Ophthalmology that about 11 million people over the age of fifty experience blindness as a result of AMD. Hence making it a supple market for AMD related treatments. Obesity-related macular degeneration is also on the rise in North America, along with high blood pressure from an erratic lifestyle.
Advances in research and development in Europe and Asia-Pacific have enabled more patients to see more clearly. The African continent, particularly the Sahara subcontinent, has experienced a significant increase in dry age-related macular degeneration due to lack of vitamin A and poor dietary standards. Thus making this region the key player for pharmaceutical companies to invest in.
The key companies that are invested into creating feasible solutions for AMD are Pfizer, Bayer AG, Regenron Pharmaceutical Inc., GlaxoSmithKline plc, and Novartis AG.
Dry Age-Related Macular Degeneration Market Growth
The Dry Age-Related Macular Degeneration Market Overview is led by dry and wet drug solutions that treat this degenerative disease. Wet age-related AMD will soon see a jump of 95% in the year 2022. After the impact of COVID-19, it has been observed that wet macular degeneration has affected most of the ageing population. In this type, there is an atypical growth of blood vessels beneath the retina, causing it to bleed create vision obstruction. Developed countries have introduced intraocular anti-VEGF injections for patients suffering from wet AMD, thus increasing treatment capacity globally.
In recent years, Stargardt disease, a genetically inherited retinal disorder that has become dominant among the younger population, has given impetus for research towards macular degeneration drugs.
Lucentis, Avastin, Eylea and Visudyne are some of the prominent drugs available in the market to treat dry age-related macular degeneration. The Lucentis market has grown rapidly in developed countries since the government introduced healthcare benefits for the elderly through affordable treatments.
Dry Age-Related Macular Degeneration Market Value
It has been noted that off-label drugs are getting more popular due to their affordability than on-label drugs to treat AMD. An off-label drug like Avastin is sold rapidly in the market for patients who can get treated within their income budget.
On a case-by-case basis, the market is segmented into intravenous and intravitreous. It is said that the intravitreal segment dominates the market because it is most effective because of the targeted distribution of drugs. Furthermore, the majority of anti-VEGF injections are given intravitreally or intraocular.
- Recent data released by the World Bank statistics indicate that the older generation living above 65% is rising. They represent approximately 8.873% of the population, indicating that patients with AMD will increase due to chronic diseases and diseases.
Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013